Corcept Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CORT and other ETFs, options, and stocks.

About CORT

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. 

CEO
Joseph K. Belanoff
CEOJoseph K. Belanoff
Employees
500
Employees500
Headquarters
Redwood City, California
HeadquartersRedwood City, California
Founded
1998
Founded1998
Employees
500
Employees500

CORT Key Statistics

Market cap
8.14B
Market cap8.14B
Price-Earnings ratio
85.75
Price-Earnings ratio85.75
Dividend yield
Dividend yield
Average volume
594.95K
Average volume594.95K
High today
$78.98
High today$78.98
Low today
$74.93
Low today$74.93
Open price
$75.10
Open price$75.10
Volume
541.60K
Volume541.60K
52 Week high
$117.33
52 Week high$117.33
52 Week low
$49.00
52 Week low$49.00

Stock Snapshot

Corcept Therapeutics(CORT) stock is priced at $77.29, giving the company a market capitalization of 8.14B. It carries a P/E multiple of 85.75.

On 2025-11-22, Corcept Therapeutics(CORT) stock moved within a range of $74.93 to $78.98. With shares now at $77.29, the stock is trading +3.1% above its intraday low and -2.1% below the session's peak.

Trading volume for Corcept Therapeutics(CORT) stock has reached 541.6K, versus its average volume of 594.95K.

The stock's 52-week range extends from a low of $49.00 to a high of $117.33.

The stock's 52-week range extends from a low of $49.00 to a high of $117.33.

CORT News

Simply Wall St 2d
Patent Uncertainty and Drug Launch Timing Poise a Pivotal Question for Corcept Therapeutics

Wolfe Research recently initiated coverage on Corcept Therapeutics with a Peerperform rating, highlighting both the company’s ongoing patent litigation and anti...

Patent Uncertainty and Drug Launch Timing Poise a Pivotal Question for Corcept Therapeutics
TipRanks 4d
Corcept Therapeutics initiated with a Peer Perform at Wolfe Research

Wolfe Research analyst Kalpit Patel initiated coverage of Corcept Therapeutics (CORT) with a Peer Perform rating and no price target The firm’s analysis of Cush...

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.